Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-α)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-β) treatment

Clinical and Experimental Immunology

Volumn 120, Issue 1, 2000, Pages 147-153

  Ozenci V ^a   Kouwenhoven, M ^a   Huang, Y M ^a   Kivisakk P ^a   Link, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytokines; ELISPOT assay; Multiple sclerosis

Indexed keywords

BETA INTERFERON; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL SECRETION; CEREBROSPINAL FLUID CYTOLOGY; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME ASSAY; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 0034025811     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01175.x     Document Type: Article

References (42)

1. Steinman L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 1996; 85:299-302.
2. Diab A, Zhu J, Xiao BG, Muslafa M, Link H. High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats. J Neuropathol Exp Neurol 1997; 56:641-50.
3. Navikas V, Link H. Cytokines and the pathogenesis of MS. J Neurosci Res 1996; 45:322-33.
4. Franciota DM, Grimaldi LME, Martino GV, Piccolo G, Bergamaschi R, Cittero A, Melzi d'Eril GV. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 1989; 26:787-9.
5. Navikas V, Be B, Link J et al. Augmented expression of tumor necrosis factor-α and lymphotoxin mRNA in mononuclear cells in multiple sclerosis and optic neuritis. Brain 1996; 119:213-23.
6. Maimone D, Gregory S, Arnason BG, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991; 32:67-74.
7. Navikas V, Matusevicius D, Söderström M, Fredrikson S, Kivisäkk P, Ljungdahl Å, Höjeberg B, Link H. Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. J Neuroimmunol 1996; 64:63-69.
8. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, Fredrikson S, Ekre HP, Link H. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991; 21:1461-8.
9. Link J, Söderström M, Olsson T, Höjeberg B, Ljundahl Å, Link H. Increased transforming growth factor-β, interleukin-4 and interferon-γ in multiple sclerosis. Ann Neurol 1994; 36:379-86.
10. Navikas V, Link J, Palasik W, Söderström M, Fredrikson S, Olsson T, Link H. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand J Immunol 1995; 41:171-8.
11. Salmaggi A, Dufour A, Eoli M, Corsini E, La Mantia L, Massa G, Nespolo A, Milanese C. Low serum interleukin levels in multiple sclerosis: Further evidence for decreased systemic immunosuppression? J Neurol 1996; 243:13-17.
12. Barnes A. Measurements of serum cytokines. Lancet 1998; 352:324-5.
13. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45:1277-85.
14. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352:1491-7.
15. Arnason BW, Reder AT. Interferons and multiple sclerosis. Clin Neuropharm 1994; 154:495-547.
16. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13:227-31.
17. Kurtzke JF. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33:1444-52.
18. Osserman KE, Genkins G. Studies in myasthenia gravis: Review of twenty year experience in over 1200 patients. Mount Sinai J Med 1971; 38:497-537.
19. Czerkinsky CC, Andersson G, Ekre HP, Nilsson LÅ, Klareskog L, Ouchterlony Ö. Reverse ELISPOT assay for clinical analysis of cytokine production. I. Enumeration of gamma-interferon secreting cells. J Immunol Methods 1988; 110:29-36.
20. Link H, Olsson O, Sun J et al. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest 1991; 87:2191-6.
21. Özenci V, Kouwenhoven M, Huang YM, Xiao BG, Kivisäkk P, Fredrikson S, Link H. Multiple sclerosis: Levels of IL-10 secreting blood mononuclear cells are low in untreated patients but augmented during IFN-β;-1b treatment. Scand J Immunol 1999; 49:554-61.
22. Rönnelid J, Klareskog L. A comparison between ELISPOT methods for the detection of cytokine producing cells: Greater sensitivity and specificity using ELISA plates as compared to nitrocellulose membranes. J Immunol Methods 1997; 15:17-26.
23. Tanguay S, Killion J. Direct comparison of ELISPOT and ELISA based assays for detection of individual cytokine secreting cells. Lymphokine Cytokine Res 1994; 12:903-11.
24. Shirai A, Holmes K, Klinman DM. Detection and quantitation of cells secreting IL-6 under physiological conditions in BALB/c mice. J Immunol 1993; 150:793-9.
25. O'Mahony L, Holland J, Jackson J, Feigherty C, Hennessy TPJ, Mealy K. Quantitative intracellular cytokine measurement: Age-related changes in proinflammatory cytokine production. Clin Exp Immunol 1998; 113:213-9.
26. Nehlsen-Cannarella SL. Cellular response to moderate and heavy exercise. Can J Physiol Pharmacol 1998; 76:485-9.
27. 1 rats. J Clin Immunol 1997; 17:85-95.
28. Ackerman KD, Martino M, Heyman R, Moyna RH, Rabin BS. Stressor-induced alternations of cytokine production in multiple sclerosis patients and controls. Psychosom Med 1998; 60:484-91.
29. Lu CZ, Fredrikson S, Xiao BG, Link H. Tnterleukin-2 secreting cells in multiple sclerosis and controls. J Neurol Sci 1993; 120:99-106.
30. Zhang M, Tracey KJ. Tumor necrosis factor. In: Thomson A, ed. The cytokine handbook, 3rd edn. San Diego: Academic Press, 1999:517-48.
31. Becher B, Blain M, Giacomini PS, Antel JP. Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen presenting cell-derived IL-12. J Immunol 1999; 162:684-8.
32. Gadient RA, Otten UH. Interleukin-6 (IL-6) - a molecule with both beneficial and destructive potentials. Prog Neurobiol 1997; 52:379-90.
33. Maimone D, Guazzi GC, Annunziata P. IL-6 detection in multiple sclerosis brain. J Neuro Sci 1997; 146:59-65.
34. Okuda Y, Sakoda S, Bernard CCA, Fujimara H, Saeki Y, Kishimato T, Yanagihara T. IL-6 deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int Immunol 1998; 10:703-8.
35. Tilg H, Dinarello CA, Mier JW. IL-6 and AAPs: Anti-inflammatory and immunosuppressive mediators. Immunol Today 1997; 18:428-32.
36. de Waal Malefyt R, Abrams J, Bennelt B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20.
37. Xiao BG, Bai XF, Zhang GX, Link H. Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats. J Neuroimmunol 1998; 84:230-7.
38. Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC. Cerebrospinal fluid interleukin 6 in amyotropic parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 1998; 154:194-9.
39. Rep MHG, Hintzen RQ. Polman CH, van Lier RAW. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T cells. J Neuroimmunol 1996; 67:111-8.
40. Porrini AM, Gambi D, Reder AT. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol 1995; 61:27-34.
41. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis. Neurology 1998; 51:682-9.
42. Rudick RA, Ransohoff RM, Lee JC, Peppler R, Yu M, Mathisen PM, Tuohy VK. In vivo effects of Interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50:1294-300.